All In Biotech

Drug Trial Radar · NCT04208529

A Long-term Follow-up Study in Participants Who Received CTX001

A Long-term Follow-up Study of Subjects With β-thalassemia or Sickle Cell Disease Treated With Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001)

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

160

Planned (sponsor's estimate)

Start

Jan 20, 2021

Primary completion

Sep 30, 2039

Study completion Sep 30, 2039

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
Collaborators
CRISPR Therapeutics
First posted
Dec 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-site, open- label rollover study to evaluate the long-term safety and efficacy of CTX001 in pediatric and adult participants who received CTX001 in parent studies 111 (NCT03655678) 141 (NCT05356195) or 161 (NCT05477563) (transfusion-dependent β-thalassemia \[TDT\] studies) or Study 121 (NCT03745287) or 151 (NCT05329649) or 161(NCT05477563) (severe sickle cell disease \[SCD\] studies).

Conditions

  • Beta-Thalassemia
  • Thalassemia
  • Sickle Cell Disease
  • Hematologic Diseases
  • Hemoglobinopathies
  • Genetic Diseases, Inborn
  • Sickle Cell Anemia

Interventions

  • CTX001Biological

    CTX001 infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. New malignanciesTime frame: Signing of informed consent up to 15 years post CTX001 infusion
  2. New or worsening hematologic disordersTime frame: Signing of informed consent up to 15 years post CTX001 infusion
  3. All-cause mortalityTime frame: Signing of informed consent up to 15 years post CTX001 infusion
  4. Serious adverse events (SAEs)Time frame: Signing of informed consent up to 15 years post CTX001 infusion
  5. CTX001-related adverse events (AEs)Time frame: Signing of informed consent up to 15 years post CTX001 infusion

Locations

20 sites in 6 countries. Site status is shown where the registry gives one.

  • Lucile Packard Children's Hospital

    Palo Alto, California

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Hematology

    Chicago, Illinois

  • Herbert Irving Pavilion - Hematology

    New York, New York

  • New York Presbyterian Hospital - Morgan Stanley Children's Hospital

    New York, New York

  • Levine Children's Hospital - Hematology

    Charlotte, North Carolina

  • The Children's Hospital of Philadelphia - Hematology

    Philadelphia, Pennsylvania

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • TriStar Medical Group Children's Specialists - Pediatric Oncology

    Nashville, Tennessee

  • Methodist Healthcare System of San Antonio, Methodist Hospital, Methodist Children's Hospital

    San Antonio, Texas

  • Hopital Universitaire des Enfants Reine Fabiola (HUDERF) - Hematology

    Brussels, Belgium

  • Hospital for Sick Children - Hematology

    Toronto, Canada

  • Toronto General Hospital - Hematology

    Toronto, Canada

  • St. Paul's Hospital - Hematology

    Vancouver, Canada

  • University Hospital Duesseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology

    Düsseldorf, Germany

  • Center for Pediatric Clinical Studies (CPCS)

    Klinik Für Kinder- Und Jugendmedizin, Germany

  • Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine

    Regensburg, Germany

  • IRCSS Ospedale Pediatrico Bambino Gesu - Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica

    Rome, Italy

  • Great Ormond Street Hospital for Children

    London, United Kingdom

  • Hammersmith Hospital - Haematology Dept

    London, United Kingdom

  • University College London Hospital NHS Foundation - Main

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.